Effectiveness of Second-Line Pembrolizumab Monotherapy for the Treatment of Nonsmall Cell Lung Cancer: A Retrospective-Single Institution Study of 52 Vietnamese Patients
Second-line pembrolizumab has a good disease control rate and prolonged survival and is a viable option for the treatment of Vietnamese NSCLC patients. Further clinical studies are necessary to determine the effectiveness of administering a low dose of pembrolizumab in this setting, particularly in Asian population.
Authors
- Tai Van Nguyen (ORCID: https://orcid.org/0000-0003-1363-8161)
- Chu Van Nguyen (ORCID: https://orcid.org/0000-0001-8928-5089)
- Thai Nguyen (ORCID: https://orcid.org/0000-0002-5742-3851)
- Kien Hung (ORCID: https://orcid.org/0000-0001-6059-7046)
- Quang Van Le (ORCID: https://orcid.org/0009-0003-5286-3940)
- Thi Bich Phuong Nguyen
- Anh Tu
Institutions
- Hanoi Medical University (VN)
- Vietnam National Children's Hospital (VN)
Publication Details
- Journal
- Clinical Medicine Insights Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/11795549251359142
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05